Black Americans reported more positive views of psychedelic-assisted therapy than White Americans after receiving brief psychoeducation about MDMA and psilocybin-assisted therapy. Among 294 adults (44% Black/African American or Mixed Race with Black ancestry, 56% White American; average age 36.3 years), psychoeducation increased interest and positivity across both groups. Greater depression and PTSD symptom severity was linked to higher baseline interest in both groups, and Black participants with more severe depression showed even greater interest and more positive views. The findings suggest that research groups, not potential participants, are responsible for diversifying clinical trial samples and that rebuilding trust and providing culturally attuned interventions is needed.
Black Americans are underrepresented in psychedelic trials despite high mental health needs. In four focus groups with low-income, urban Black participants, three themes emerged: informed hesitation mixed with openness; trust, autonomy, and choice; and practical solutions to improve access. Participants voiced concerns about racism in healthcare, research, drug policy, and criminalization. They emphasized building trust through community investment, autonomy, and addressing barriers like childcare and transportation. The findings support centering Black Americans' needs in psychedelic-assisted therapy to improve access and care quality.